Optometric Management Magazine

Sight Sciences, Inc.

Exposure to indigo light prevented myopia in a tree shrew model with human-like visual characteristics, according to research led by Cincinnati Children’s and the University of Alabama at Birmingham (UAB). The study, published online August 18 in Cell Reports Medicine, focused on short-wavelength indigo light, which is abundant in sunlight but is poorly represented in standard white LED lighting.

The Centers for Medicare and Medicaid Services (CMS) has established final 2026 Medicare payment amounts for Balance Ophthalmics’s Fsyx Ocular Pressure Adjusting Pump (OPAP) and associated goggles, with the rates taking effect October 1. Under HCPCS Level II code E2403, the Fsyx pump will be reimbursed as a capped rental at approximately $1,352.58 per month for months 1 through 3 and $1,014.44 per month for months 4 through 13.

DefEye Inc. announced in a press release the publication of a peer-reviewed article highlighting the use of Biovance Ocular decellularized basement membrane (DBM) in almost 1,000 patients suffering from neurotrophic keratitis (NK). Titled “Retrospective Evaluation of Successive Biovance Decellularized Basement Membrane Tissue Grafts for the Management of Chronic Subclinical and Stage 1 Neurotrophic Keratitis," the article was authored by Brandon D. Ayres, MD; Nicole R.

The World Council of Optometry (WCO) and Alcon dry eye initiative is partnering with the International Association of Contact Lens Educators (IACLE) to help university instructors easily access the program’s range of digital learning tools including the WCO Alcon Dry Eye Wheel and the Dry Eye Management Map. IACLE members can gain direct access from the IACLE Teaching Online Platform (IACLETOP) learning management system.

Zeiss Medical Technology announced the 510k clearance from the US Food and Drug Administration (FDA) for Zeiss Clinic 360, an all-in-one cloud and browser-based software solution. According to a company press release, Zeiss Clinic 360 combines diagnostic and medical data into a comprehensive patient view that allows clinicians to evaluate disease progression, support treatment decisions, and improve workflow efficiency.

EyePoint reported top-line results from the phase 3 LUGANO trial of Duravyu (vorolanib intravitreal insert) 2.7 mg in patients with wet age-related macular degeneration (AMD). The study missed its primary endpoint in the full dataset but met several secondary endpoints. The primary endpoint assessed change from baseline in best-corrected visual acuity compared with on-label 2 mg aflibercept. Duravyu did not achieve noninferiority in the full analysis.

On Friday, Aug. 21, join optometrists from across the country for Spectrum of Optometry—a complimentary half-day virtual program featuring timely education from nationally recognized faculty that is being provided by and co-sponsored by Conexiant Education and Northeastern State University Oklahoma College of Optometry. The event, which will run from 10 AM to 3:30 PM EDT, will feature 4 education sessions as well as industry presentations.

WaveFront Dynamics Inc. announced 2 new integrations with Bausch + Lomb and Wave Eye Care, designed to provide eyecare professionals with greater flexibility in premium scleral lens selection and patient care, the company said in a press release.

Tarsus Pharmaceuticals said it has agreed to acquire Alkeus Pharmaceuticals, adding the investigational oral retinoid gildeuretinol (formerly ALK-001) and a phase 3 program in Stargardt disease to its expanding ophthalmic pipeline. According to Tarsus, the deal strengthens its presence in retina following its previous acquisition of iRenix Medical. Gildeuretinol is an investigational oral therapy designed to reduce the accumulation of vitamin A dimers while preserving the normal visual cycle.